Bibliography
- ANONYMOUS: Report of the national high blood pressure education program working group on high blood pressure in pregnancy [comment]. Am. J. Obstet. Gynecol. (2000) 183(1):S1-S22.
- LOWE DT: Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide (2000) 4(4):441-458.
- ISLAMI D, SHOUKIR Y, DUPONT P, CAMPANA A, BISCHOF P: Is cellular fibronectin a biological marker for pre-eclampsia? Eur. J. Obstet. Gynecol. Reprod. Biol. (2001) 97(1):40-45.
- FRIEDMAN SA, SCHIFF E, EMEIS JJ, DEKKER GA, SIBAI BM: Biochemical corroboration of endothelial involvement in severe preeclampsia. Am. J. Obstet. Gynecol. (1995) 172(1 Part 1):202-203.
- HALIM A, KANAYAMA N, EL MARADNY E et al.: Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am. J. Obstet. Gynecol. (1996) 174(1 Part 1):272-277.
- KRAUSS T, KUHN W, LAKOMA C, AUGUSTIN HG: Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am. J. Obstet. Gynecol. (1997) 177(2):443-449.
- GREER IA, LYALL F, PERERA T, BOSWELL F, MACARA LM: Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet. Gynecol. (1994) 84(6):937-940.
- VINCE GS, STARKEY PM, AUSTGULEN R, KWIATKOWSKI D, REDMAN CW: Interleukin-6, TNF and soluble TNF receptors in women with pre-eclampsia. Br. J. Obstet. Gynaecol. (1995) 102(1):20-25.
- MAYNARD SE, MIN JY, MERCHAN J et al.: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Investig. (2003) 111(5):649-658.
- LEVINE RJ, LAM C, QIAN C et al.: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. (2006) 355(10):992-1005; erratum: N. Engl. J. Med. (2006) 355(17):1840.
- LEVINE RJ, MAYNARD SE, QIAN C et al.: Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. (2004) 350(7):672-683.
- LEVINE RJ, THADHANI R, QIAN C et al.: Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 293(1):77-85.
- VENKATESHA S, TOPORSIAN M, LAM C et al.: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. (2006) 12(6):642-649.
- GAROVIC VD, WAGNER SJ, TURNER ST et al.: Urinary podocyte excretion as a marker for preeclampsia. Am. J. Obstet. Gynecol. (2007) 196(4):320, E1-E7.
- WAGNER SJ, CRAICI I, GAROVIC VD: The effect of early diagnosis and treatment on maternal and fetal outcomes in patients with HELLP syndrome. Biochemia Medica (2007) 17(1):61-70.
Patent
- VOROTELIAK VICTOR: WO2007030889 (2007).